Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 2/20 | 0.36 |
| ▸ | ADH1B | P00325 | 1/20 | 0.30 |
| ▸ | ADH1C | P00326 | 1/20 | 0.30 |
| ▸ | ADH1A | P07327 | 1/20 | 0.30 |
| ▸ | ADH4 | P08319 | 1/20 | 0.30 |
| ▸ | ADH7 | P40394 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23064261 | 0.96 | ACLY (0.36) | ACLYADH1BADH1CADH1AADH4 | |
| SCHEMBL23064336 | 0.94 | ACLY (0.35) | ACLYADH1BADH1CADH1AADH4 | |
| SCHEMBL7689061 | 0.91 | INPP5A (0.33) | — | |
| SCHEMBL7692422 | 0.79 | ACLY (0.36) | ACLY | |
| SCHEMBL23064384 | 0.74 | ACLY (0.38) | ACLY | |
| SCHEMBL23868226 | 0.70 | ACACB (0.38) | ACLYADH1BADH1CADH1AADH4 | |
| SCHEMBL7688948 | 0.70 | ACLY (0.32) | ACLY | |
| SCHEMBL7688909 | 0.70 | ADH1B (0.43) | ACLYADH1BADH1CADH1AADH4 | |
| SCHEMBL3961106 | 0.69 | — | — | |
| SCHEMBL10154033 | 0.68 | JAK1 (0.39) | ACLYADH1BADH1CADH1AADH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4364739-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING KIDNEY INJURY, AND AUTOPHAGY ACTIVATOR | OSAKA UNIVERSITY (JP) | 2024-05-08 | — | — | EP | disclosed |
| US-11976062-B2 | Benzisoxazole compound | OSAKA UNIVERSITY (JP) | 2024-05-07 | — | — | US | disclosed |
| EP-3789383-B9 | INHIBITORS OF THE TRPC3 OR TRPC6 CHANNEL | UNIV OSAKA (JP) | 2024-02-28 | — | — | EP | disclosed |
| CN-117580577-A | Pharmaceutical composition for preventing and/or treating kidney injury and autophagy activator | 国立大学法人大阪大学 | 2024-02-20 | — | — | CN | disclosed |
| EP-3789383-B1 | INHIBITORS OF THE TRPC3 OR TRPC6 CHANNEL | UNIV OSAKA (JP) | 2023-11-29 | — | — | EP | disclosed |
| WO-2023163203-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING RENAL DISEASE | 国立大学法人大阪大学 | 2023-08-31 | — | — | WO | disclosed |
| WO-2023132208-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING HEART FAILURE | 国立大学法人大阪大学 | 2023-07-13 | — | — | WO | disclosed |
| US-20230114195-A1 | BENZISOXAZOLE COMPOUND | KYOTO UNIVERSITY (JP) | 2023-04-13 | — | — | US | disclosed |
| US-11548882-B2 | Benzisoxazole compound | OSAKA UNIVERSITY (JP) | 2023-01-10 | — | — | US | disclosed |
| WO-2023276828-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING KIDNEY INJURY, AND AUTOPHAGY ACTIVATOR | 国立大学法人大阪大学 | 2023-01-05 | — | — | WO | disclosed |
| US-20210238171-A1 | BENZISOXAZOLE COMPOUND | INTER-UNIVERSITY RESEARCH INSTITUTE CORPORATION NATIONAL INSTITUTES OF NATURAL SCIENCES (JP) | 2021-08-05 | — | — | US | disclosed |
| WO-2021079962-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND/OR TREATMENT OF HEARING LOSS | 国立大学法人大阪大学 | 2021-04-29 | — | — | WO | disclosed |
| EP-3789383-A1 | BENZISOXAZOLE COMPOUND | Osaka University (JP) | 2021-03-10 | — | — | EP | disclosed |
| CN-112204017-A | Benzisoxazole compounds | 国立大学法人大阪大学 | 2021-01-08 | — | — | CN | disclosed |
| WO-2002000622-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238171-A1 | BENZISOXAZOLE COMPOUND | CBR1, CYP2S1, CYP2E1 | ACLY 1822/4885ADH1B 1207/4885ADH1C 1170/4885 |
| US-11976062-B2 | Benzisoxazole compound | CBR1, CYP2S1, CYP2E1 | ACLY 1857/4885ADH1B 1212/4885ADH1C 1167/4885 |
| US-11548882-B2 | Benzisoxazole compound | CBR1, CYP2S1, CYP2E1 | ACLY 1822/4885ADH1B 1207/4885ADH1C 1170/4885 |
| US-20230114195-A1 | BENZISOXAZOLE COMPOUND | CBR1, CYP2S1, CYP2E1 | ACLY 1929/4885ADH1B 1196/4885ADH1C 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.